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Abstract The characteristic hemorrhages of acute
promyelocytic leukemia (APL) are caused in part by the
high expression of tissue factor (TF) on leukemic cells,
which also produce TNF and IL-1β, proinflammatory cy-
tokines known to increase TF in various cell types.
Exposure of NB4 cells, an APL cell line, to all-trans
retinoic acid (ATRA) or arsenic trioxide (ATO) rapidly
and strongly reduced TF mRNA. Both drugs also reduced
TNF mRNA, but later, and moreover increased IL-1β
mRNA. The effect on procoagulant activity of cells and
microparticles, as measured with calibrated automated
thrombography, was delayed and only partial at 24 h.
TNF and IL-1β inhibition reduced TF mRNA and activity
only partially. Inhibition of the inflammatory signaling
intermediate p38 reduced TF mRNA by one third but
increased TNF and IL-1β mRNA. NF-κB inhibition re-
duced, within 1 h, TF and TNF mRNA but did not change
IL-1β mRNA, and rapidly and markedly reduced cell sur-
vival, with procoagulant properties still being present. In
conclusion, although we provide evidence that TNF, IL-
1β, and their signaling intermediates have a regulatory
function on TF expression by NB4 APL cells, the effect
of ATRA and ATO on TF can only partially be accounted
for by their impact on these cytokines.
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Introduction
The pers is tent and worr isome hal lmark of acute
promyelocytic (M3) leukemia (APL) is the high risk of se-
vere , of ten fa ta l , b leeding compl ica t ions [1–6] .
Pathogenesis of the coagulopathy is complex and includes
an insufficient production of platelets, as well as dissemi-
nated intravascular coagulation (DIC) [2, 6–9], caused, at
least in part, by tissue factor (TF) expressed on the leukemia
cells and on leukemia cell-derived microparticles express-
ing TF and procoagulant phosphatidylserine on their sur-
face [10–14]. Fibrinolysis, mediated by t-PA bound to
annexin 2 on the leukemia cell, is another important factor
contributing to hemorrhagic complications [15].
Treatment of APL patients with all-trans retinoic acid
(ATRA) or arsenic trioxide (ATO) leads, over a period of
1 to 3 weeks, to normalization of plasma concentrations
of D-dimers and thrombin–antithrombin complexes [7, 8,
16, 17] and of TF mRNA in patient-derived bone marrow
cells [8, 16, 18]. Studies performed with cultured bone
marrow cells from APL patients revealed that exposure
to ATRA reduced cell-associated procoagulant activity
[19]. Experiments using NB4 cells, an APL cell line that
presents the characteristic 15;17 chromosomal transloca-
tion, showed that exposure to ATRA or ATO resulted in a
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reduction of TF mRNA and antigen [18, 20–22] as well as
of TF activity [12]. However, as therapy by ATRA or
ATO (mostly) leads to APL cell apoptosis and thus gen-
eration of microparticles [10, 23], it is possible that
ATRA-mediated differentiation of APL cells leads to a
transient increase in procoagulant activities, despite its
downregulating effect on TF mRNA [13]. A further factor
that has to be taken into account is the production by APL
cells of proinflammatory cytokines, such as TNF and IL-
1β [24, 25]. This may be of clinical relevance because
these cytokines are capable, among other properties, of
increasing TF production in monocytes and endothelial
cells and, considering that NB4 cells express TNF recep-
tor 1 [26], could also contribute to TF production by APL
cells.
In the present study, we used NB4 cells to investigate in
more detail the time course of the effects of ATRA and ATO
on TF activity and on expression of the proinflammatory cy-
tokines TNF and IL-1β. In addition, we investigated to what
extent TF production by NB4 cells depends on TNF and IL-
1β they also produce and whether it is affected by interfering
with the inflammatory signaling intermediates p38, jun ki-
nase, and NF-κB. We observed that exposure of NB4 cells
to ATRA led within 1 h to a reduction of TF mRNA and to
a reduction of TNF mRNA but only after 6 h. Exposure to
ATO also induced a reduction of TF and TNF mRNA, which
was detectable only after 3 and 6 h, respectively. Both ATRA
and ATO increased IL-1β mRNA several fold. A partial re-
duction in TF antigen and TF activity was evident only after
24 h of ATRA or ATO treatment. Inhibition of TNF and, to a
lesser extent, of IL-1β only partially reduced TF mRNA.
Inhibition of p38 reduced TF mRNA but strongly increased
TNF and IL-1βmRNA, while inhibition of JNK had no effect
on TF and TNF mRNA but reduced IL-1βmRNA. Inhibition
of NF-κB reduced TF and TNF mRNA in NB4 cells with
more than 50% within 1 h but also reduced cell survival with
a half-life of approximately 6 h.
Materials and methods
Reagents
ATRA and ATO were from Sigma-Aldrich. Adalimumab
(Humira®), a TNF activity-blocking antibody, was from
Abbott Laboratories, and Anakinra (Kineret®), an IL-1 recep-
tor antagonist, was from Swedish Orphan Biovitrum. BAY11-
7085, an inhibitor of NF-κB, was from Biomol. The p38 in-
hibitors SB203580, SB202190, and Birb796 were from
Sigma-Aldrich, Biomol, and Axon Medchem, respectively.
The jun kinase inhibitor SP600125 was from Tocris
Biosciences.
Cell lines used
NB4 APL and HL-60 acute myeloid leukemia cells were ob-
tained from the German Collection of Microorganisms and
Cell Cultures (http://www.dsmz.de). NB4 cells contain the
15;17 chromosomal translocation and are used as a standard
model for investigations on the mechanisms of cellular
responses of APL cells, whereas HL60 cells lack the 15;17
chromosomal translocation. NB4 and HL60 cells were
cultured in RPMI 1640 medium (Gibco) + 10% fetal bovine
serum (Pan Biotech) and 1% of penicillin/streptomycin.
U937-PR9 cells, stably transfected with DNA encoding the
PML-RARα fusion protein under control of the
metallothionin promoter, as well as the corresponding control
U-937MT cells [27], were a kind gift from Prof. P.G. Pelicci
(Department of Experimental Oncology, European Institute of
Oncology, 20141 Milan, Italy). The cells were cultured at a
density of 106 cells/ml in RPMI 1640 medium + 10% fetal
bovine serum and 1% of penicillin/streptomycin. Cells were
used for up to ten passages after having been received. They
were isolated by centrifugation for 5 min at 300×g and 4 °C
and cell-derived microparticles by centrifugation of the cell
supernatant for 5 min at 1500×g to remove cell debris follow-
ed by a further centrifugation for 30 min at 20,000×g. Cells
and microparticles were suspended in Dulbecco’s phosphate-
buffered saline (Gibco, cat. no. 14190-094). Coagulation stud-
ies with the supernatant prepared as just above described will
be referred to as Bmicroparticle-associated coagulant activi-
ties.^ Those studies were thus performed with both cell sus-
pension (50,000/ml) and microparticles (suspended in an
equivalent volume as the cells).
Quantitative reverse transcriptase real time PCR (qPCR)
assay for TF, TNF, and IL-1β mRNA
Total cellular RNA was isolated using the TRIzol reagent
(Invitrogen) and reverse transcribed using the Improm-II re-
verse transcriptase system from Promega. Thereafter, qPCR
was performed as described previously [28] using theΔΔCT
method and GAPDH as the control housekeeping gene. The
following forward and reverse primer sequences, respectively,













TF and CD11c, a marker of granulocytic differentiation, were
analyzed with flow cytometry using a BD Biosciences Accuri
C6 flow cytometer. APC-labeled antibodies to TF (CD142)
and its isotype (IgG1kappa) matched APC-labeled control
antibodies (IgG-APC) were from eBioscience (cat. nos. 17-
1429 and 17-4714, respectively) and phycoerythrin-labeled
antibodies to CD11c and its isotype (IgG1kappa) matched
PE-labeled control antibodies (IgG-PE) were from BD
Pharmingen (cat. nos. 555392 and 555749, respectively).
The cells were first washed in phosphate-buffered saline
(PBS) + 1% bovine serum albumin (PBS/BSA) and 0.01%
sodium azide. Then, 200,000 cells were incubated for
30 min at room temperature with 0.6 μl IgG-APC + 20 μl
IgG-PE or with 5 μl CD142-APC + 20 μl CD11c-PE in a total
volume of 50 μl PBS/BSA. Thereafter, 500 μl of PBS/BSA
was added and the cells centrifuged for 5 min at 200×g and
4 °C. The cells were washed once with 500 μl of PBS/BSA
and resuspended in 200 μl PBS/BSA. The cell suspensionwas
stored on ice in the absence of light. Five minutes before flow
cytometry analysis, 5 μl of 1 mg/ml of 7-amino actinomycin
(7-AAD; R&D systems) was added to exclude dead cells from
analysis.
Coagulation assays
TF activity was quantified with a factor FXa generation assay
[29], and overall coagulant activity was assessedwith a throm-
bin generation assay (calibrated automated thrombography)
[30]. The contribution of TF to activities measured in those
assays was explored by comparing activities in the presence
and absence of 10 μg/ml of a murine monoclonal anti-TF
antibody (Ref 4509, Sekisui Diagnostics). This anti-TF anti-
body concentration was shown to be sufficient to completely
block factor FXa generation activity on LPS-treated human
endothelial cells [31].
Factor Xa generation assay In short, hundredmicroliters of a
suspension of cells (50,000/ml) or microparticles (suspended
in an equivalent volume as the cells) was incubated with 5 μl
of human coagulation factor X (at 3.4 μM; HCX-0500,
Haematologic Technologies Inc.) and 10 μl of factor VIIa (at
50 nM, Novoseven, Novo Nordisk). The samples were incu-
bated for 15 min at 37 °C and further FXa generation stopped
by addition of 50 μl of 15 mMEDTA. Thereafter, 50 μl of the
FXa chromogenic substrate SFXA-11 (Hyphen Biomed) was
added at 3.9 mM and the mixture incubated for a further
15 min at 37 °C. After addition of 100 μl of 1 M H2SO4, the
absorbance was read at 405 nm and compared to that of a
standard curve made using different concentrations of bovine
factor FXa (Hyphen Biomed). Results are expressed as rela-
tive to the activity of unexposed NB4 cells.
Calibrated automated thrombography (CAT) assay This
was done according to the manufacturer’s instructions using
reagents and procedures provided by Diagnostica Stago.
Suspensions of cells (50,000/ml) or microparticles (suspended
in an equivalent volume as the cells) were mixed with normal
plasma and fluorescence development measured with a
Fluoroskan Ascent (Thermo electron corporation) microplate
fluorimeter and analyzed using Thrombinoscope™ software
(Diagnostica Stago).
Statistical analysis
Data are presented as means ± standard error of the mean
(SEM). The significance of differences was assessed using
the paired Student’s t test.
Results
Effect of ATRA and ATO on mRNA levels of TF, TNF,
IL-1β, and CD11c in NB4 and HL-60 cells
The inflammatory cytokines TNF and IL-1β are known to be
produced by APL cells and are capable of increasing TF ex-
pression in some cell types. We first investigated in NB4 cells
to what extent ATRA and ATO, which are nowadays standard
therapeutics in APL patients, modified mRNA levels of TF,
TNF, and IL-1β. In preliminary concentration response exper-
iments we determined after 24-h incubation, the concentra-
tions at which ATRA and ATO attained their maximal effect.
With ATRA, in NB4 cells, we observed a maximal effect
after 24 h at 0.5 μM. At this concentration, TF mRNA was
reduced by 92 ± 2% (mean ± SEM, n = 4) and TNFmRNA by
88 ± 1%. A time–response curve performed with 0.5 μM
ATRA showed that ATRA attained its maximal effect on TF
mRNA already within 1 h, whereas its inhibitory effect on
TNF mRNA was detectable only after 4 h and attained its
maximal effect of more than 80% inhibition only after 15 h
(Fig. 1, left). In contrast with its inhibitory effect on TF and
TNF mRNA, 0.5 μM ATRA increased IL-1β mRNA by
4.3 ± 0.7-fold, already within 4 h.
To assess whether these results were specific to NB4 cells,
the effects of ATRA on the expression of TF, TNF, and IL-1β
were also investigated in HL-60 cells, another myelocytic leu-
kemic cell line widely used for such in vitro studies. After 3-h
ATRA treatment, TF mRNAwas reduced by at most by 35%,
whereas no changes in TNF mRNA were observed (not
shown). Levels of IL-1β mRNA in HL-60 cells were below
the detection limit.
With ATO and NB4 cells, we observed a maximal effect at
5 μM. At this concentration, both TF and TNF mRNAwere
reduced by 60% after 6 h incubation. No further reduction was
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observed at 24 h for TNF mRNA, whereas TF mRNA was
almost undetectable after 24 h (Fig. 1, right). ATO at 5 μM
increased IL-1β mRNA levels up to threefold but only after
24 h. In HL-60 cells, ATO increased TF mRNA by up to
twofold (not shown) and had no effect on TNF mRNA.
To determine whether the effects of exposure of NB4 cells
to ATRA and ATO were correlated with their differentiation,
we performed mRNA analysis and flow cytometry analysis
for CD11c, a marker for promyelocytic cell differentiation.
Exposure to ATRA resulted in a gradual increase in CD11c
mRNA (fourfold at 6 h and tenfold at 24 h) (Fig. 1, left).
CD11c antigen at the cell surface, as assessed by flow
cytometry, was only detectable after 16 and 24 h of ATRA
treatment (not shown). The effect of ATRA on TF precedes its
effect on cell maturation, as the maximal effect of ATRA on
TF mRNAwas obtained within 1 h. In contrast to ATRA, and
as expected, ATO had no effect on CD11c mRNA (Fig. 1,
right) and CD11c antigen (not shown).
Effect of the PML-RARα fusion protein on expression
of TF, TNF, and IL-1β
As ATRA and ATO are both capable of reducing the PML-
RARα fusion protein [32], we investigated the effect of
Fig. 1 Time course of the effect
of ATRA or ATO on mRNA
levels of TF, TNF, IL-1β, and
CD11c in NB4 cells. NB4 acute
promyelocytic leukemia cells
were exposed for the indicated
time periods to 0.5 μM ATRA
(left) or 5 μMATO (right). Levels
of mRNAwere quantified by
qPCR and expressed relative to
that of the corresponding mRNA
in control (untreated cells,
incubated 24 h in medium alone)
NB4 cells. The results are the
means ± SEM of at least four
independent experiments
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specifically increasing PML-RARα on mRNA levels of TF,
TNF, and IL-1β. For this, we used the U937-PR9 cell line in
which PML-RARα production is under control of the
metallothionin promoter. In the presence of 100 μM of Zn2+,
these cells produce PML-RARα, whereas this fusion protein
is not made in the absence of Zn2+ [27]. This allows thus the
direct comparison of the effect of PML-RARα on expression
of TF, TNF, and IL-1β. Zn2+ treatment of U937-PR9 cells
resulted in an almost tenfold increase of both TF and TNF
mRNA after 48 h (Fig. 2, left and center). At this time point,
a threefold increase in IL-1β mRNA was observed (Fig. 2,
right). No changes in TF and TNF mRNAwere observed after
Zn2+ treatment of the control U937-MT cell line, which is
stably transfected with an empty plasmid containing a
metallothionin promoter (data not shown). We then studied
whether ATO, which inactivates the PML-RARα fusion pro-
tein, had an effect on TF mRNA in U937-PR9 cells pretreated
for 48 h with 100 μM Zn++. We observed that incubation of
these cells with 1 μM or 5 μM ATO reduced TF mRNA by
59 ± 7% and 89 ± 2% for 5 μMATO, respectively (mean ± SE
of three independent experiments).
Effect of ATRA and ATO on TF antigen and activity
of NB4 cells and of their microparticles
Flow cytometry analysis was performed to assess TF antigen
at the NB4 cell surface. We observed that both ATRA and
ATO reduced TF antigen. A 26% and 19% decrease in TF
antigen was observed after a 6-h exposure to ATRA or ATO,
respectively. After 24 h of exposure to ATRA or ATO, hardly
any TF antigen was seen at the NB4 cell surface. Indeed, the
flow cytometry signal for TF was only marginally higher than
the signal obtained with isotype-matched control antibodies
(Fig. 3a).
We then analyzed the effects of ATRA and ATO on
procoagulant activities expressed on NB4 cells and on NB4
cell-derived microparticles. We first determined the contribu-
tion of TF to NB4 cell or microparticle-associated FXa gen-
eration activity. We observed that co-incubation with
10 μg/ml of blocking anti-TF monoclonal antibody reduced
NB4 cell- and microparticle-associated activity by 79% and
100%, respectively. A 3-h exposure to 0.5 μMATRA reduced
cell-associated FXa generation activity by 22%, whereas ATO
had no effect (Fig. 3b). No differences in microparticle-
associated activities were observed at this time point
(Fig. 3c). After 24-h exposure, NB4 cell-associated activity
was reduced by 69 ± 19% (p < 0.001) by ATRA and by
52 ± 12% (p < 0.002) by ATO (Fig. 3b). At this time point,
ATRA and ATO reduced microparticle-associated TF activity
by 50 ± 29% (p < 0.001) and 47 ± 28% (p < 0.002), respec-
tively (Fig. 3c).
We also analyzed with the CAT assay the effect of ATRA
and ATO on procoagulant activities of NB4 cells and NB4
cell-derived microparticles. This assay takes into account the
contribution of TF, anionic phospholipids, and any other po-
tential players, even inhibitors such as thrombomodulin,
expressed by NB4 cells [20, 33, 34], to thrombin generation
[35], and is a more global and relevant assay than the FXa
generation assay. With a 24-h incubation with ATRA, we ob-
served an increase in the lag time (LT = time elapsed before
the thrombin burst) and a decrease in the slope of the ascend-
ing part of the curve (= a reduction in the presence of anionic
phospholipids), the peak height (peak = maximal thrombin
concentration) and of the area under the curve (referred to as
Bendogenous thrombin potential^—ETP = total amount of
thrombin action); this was observed both for cells and micro-
particles (Fig. 4a, b). Exposure to ATO also increased the lag
time but to a lesser extent than ATRA (Fig. 4b) and also
reduced peak height, but its effect on the area under the curve
was minimal.
Effect of inhibition of TNF or IL-1β on TF mRNA
and procoagulant activity of NB4 cells
The reduction in TF and TNF mRNA in ATRA- or ATO-
treated NB4 cells, as well as the known ability of TNF to
increase TF in monocytes and endothelial cells, raised the
question as to a possible contribution of TNF to TF expression
by these cells. Incubation of NB4 cells for 24 h with
adalimumab, an inhibitory monoclonal antibody to TNF,
Fig. 2 Effect of the PML-RARα fusion protein on mRNA levels of TF,
TNF, and IL-β in U-937-PR9 cells. U937-PR9 cells, in which PML-
RARα production is under control of the metallothionin promoter, were
incubated for up to 48 h with 100 μMof Zn2+ to stimulate the production
of the PML-RARα fusion protein. Levels of mRNA for TF (left), TNF
(center), and IL-1β (right) were quantified by qPCR and expressed
relative to that of the corresponding mRNA in control (untreated cells,
incubated 24 h in medium alone) U937-PR9 cells. The results are the
means ± SEM of at least four independent experiments
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resulted in a concentration-dependent reduction in TF mRNA
with a maximum of 28% at 10 μg/ml (Fig. 5). Increasing
adalimumab concentrations to 100 μg/ml did not lead to a




Fig. 3 Effect of ATRA and ATO on TF antigen and activity of NB4 cells
and NB4-cell-derived microparticles. a NB4 cells were exposed for the
indicated time periods to 0.5 μM ATRA or 5 μM ATO. After the
indicated time periods, TF antigen on the NB4 cell surface was
analyzed by flow cytometry. “Ctrl IgG” are flow cytometry results
obtained with an APC-labeled isotope matched control antibody and
“Ctrl TF” are flow cytometry results obtained with APC-labeled
antibodies on unexposed NB4 cells. Results are expressed as
means ± SEM of at least four independent experiments. The reduction
in TF antigen at 24 h in the ATRA or ATO treated cells with respect to the
unexposed cells (Ctrl TF) was significant with p values below 0.01. b and
c TF activity of NB4 cells (b) or NB4 cell-derived microparticles (c) after
3 or 24 h exposure to 0.5 μM ATRA or 5 μM ATO. All the results of b
and c are expressed as ratio of TF activity as compared to that of
unexposed NB4 cells at the same time point. The results are the
means ± SEM of five to seven independent experiments. The reduction
in TF activity at 24 h in the ATRA- or ATO-treated cells or derived
microparticles with respect to the unexposed cells (Ctrl) or their
microparticles was significant with p values below 0.01
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As NB4 cells also produce IL-1β, we investigated, in ad-
dition, the effect of inhibiting this inflammatory cytokine.
Incubation of NB4 cells with the IL-1β receptor antagonist
anakinra resulted in a reduction of 20% at most (Fig. 5).
a
b
Fig. 4 Effect of the agents investigated on procoagulant activities of NB4
cells or NB4 cell-derived microparticles as assessed with calibrated
automated thrombography. NB4 cells were exposed for 24 h to the
indicated agent and procoagulant activities of NB4 cells (left) or NB4
cell-derived microparticles (right) assessed with the CAT assay. a
Typical thrombogram (CAT) of unexposed (red) or ATRA treated
(green) NB4 cells or NB4 cell-derived microparticles. LT lag time (=
time elapsed before thrombin burst), peak height (= maximal thrombin
concentration), and ETP: area under the curve (= total amount of
thrombin action). b Histograms of results obtained regarding lag time,
peak height, and ETP with cells (left) or cell-derived microparticles
(right) obtained from NB4 cells exposed to 0.5 μM ATRA, 5 μM ATO,
10 μg/ml of adalimumab (anti-TNF: a TNF inhibitory antibody),
10 μg/ml of anakinra (IL1RA: an IL-1 receptor antagonist), 10 μM
SB203580 (SB203: a p38 inhibitor), or 100 μM BAY11-7085 (Bay: a
NF-κB inhibitor). Results are presented as themeans ± SEM of four to six
independent experiments. Differences were analyzed using the paired
Student’s t test. (*p < 0.05 and **p < 0.01)
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We also measured, using the CAT assay, the effect of TNF
or IL-1β inhibition on procoagulant activities of NB4 cells
and NB4 cell-derived microparticles. With anti-TNF, we only
observed a small significant increase in lag time and a de-
crease in peak height for NB4 microparticles but no effect
on area under the curve (Fig. 4b). Treatment with anakinra
had no significant effect on any of the parameters of the
CAT assay (Fig. 4b).
Effect of inflammatory signaling intermediates
on expression of TF, TNF, and IL-1β by NB4 cells
TNF and IL-1β exert their proinflammatory effects by signal-
ing intermediates including p38 MAP kinase, jun kinase
(JNK), and NF-κB. Inhibition of p38 with 10 μM of
SB202190, Birb796, or SB203580 reduced TF mRNA in
NB4 cells by 19 ± 4%, 26 ± 10%, and 38 ± 11%, respectively
(Fig. 6). In contrast, these p38 inhibitors increased mRNA of
TNF and IL-1β (Fig. 6). The strongest effect was seen with
SB202190, which increased TNF mRNA and IL-1β mRNA
by 6.2 ± 1.3-fold and 26.1 ± 4.1-fold, respectively. An inter-
mediate effect was seen with SB203580 with a 4.9 ± 0.7 and
7.1 ± 0.5-fold increase in TNF and IL-1β mRNA, respective-
ly, and the smallest effect with Birb796 with a 2.2 ± 0.3 and
3.1 ± 1.0 increase in TNF and IL-1β mRNA, respectively.
Inhibition of JNK, using 10 μM of SP600125, had no effect
on TF mRNA and reduced TNF and IL-1β mRNA by
31 ± 11% and 80 ± 2%, respectively (Fig. 6). We also mea-
sured, using the CAT assay, the effect of the p38 inhibitor
SB203580 on procoagulant activities of NB4 cells and NB4
cell-derived microparticles. No significant changes in lag
time, peak height, and area under the curve were observed
(Fig. 4b).
Inhibition of NF-κB, using 100 μMof BAY11-7085, led to
a very rapid reduction in TF and TNF mRNA. Minimal levels
were observed already after 1 h (49% and 42%, respectively;
Supplementary Fig. 1). BAY11-7085 had no effect on IL-1β
mRNA. An unexpected finding was that BAY11-7085 had a
strong effect on cell survival. After 6 h incubation with
100 μM of BAY11-7085, NB4 cell survival was only 42%,
as compared to over 95% for untreated NB4 cells and after
24 h cell survival was less than 10%. In view of this, mRNA
measurements are shown only for the time period up to 2 h.
Incubation of NB4 cells for 24 h with BAY11-7085 had no
Fig. 6 Effect of inhibition of p38 or jun kinase on mRNA levels of TF,
TNF, or IL-1β in NB4 cells. NB4 cells were exposed for 24 h to 10μMof
the p38 inhibitors SB202190, Birb796, or SB203580 or 10 μM of the jun
kinase inhibitor SP600126 and mRNA levels of TF, TNF, or IL-1β
quantified by qPCR and expressed relative to that of the corresponding
mRNA in control (unexposed cells, incubated in medium alone) NB4
cells. Results are expressed as means ± SEM of six independent
experiments. Results obtained with the p38 inhibitors are significant with
a p value <0.01
Fig. 5 Effect of inhibition of TNF or IL-1β on TF mRNA levels in NB4
cells. NB4 cells were exposed for 24 h to various concentrations of
adalimumab (a TNF inhibitory antibody) or anakinra (an IL-1 receptor
antagonist) and TFmRNA levels were quantified by qPCR and expressed
relative to that of the corresponding mRNA in control (unexposed cells,
incubated in medium alone) NB4 cells. Results are expressed as
means ± SEM of six independent experiments
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effect on procoagulant activities of NB4 cells, as measured
with the CAT assay, but reduced the lag time of and increased
peak height NB4 cell-derived microparticles (Fig. 4b).
Discussion
Human APL cells produce both TF and the inflammatory
cytokines TNF and IL-1β. This study was undertaken to in-
vestigate the effect of ATRA and ATO on the expression of
these proteins and to better understand the contribution of the
inflammatory cytokines TNF and IL-1β, as well as the signal-
ing intermediates p38, JNK, and NF-κB to TF expression by
APL cells. For this, we used the NB4 human APL cell line,
which has the 15;17 chromosomal translocation leading to the
production of the PML-RARα fusion protein [36], that is
characteristic for the majority of acute promyelocytic leuke-
mia cases [37]. NB4 cells were chosen for this study, because
the behavior of these cells was shown, in many studies, to be
comparable to that of patient-derived primary APL cells [12,
18, 34, 38–44].We also analyzed the effect of ATRA andATO
in HL-60 acute myeloid leukemia cells which lacks the 15;17
translocation [45]. Our results in NB4 cells show that ATRA
and ATO reduce TF and TNF mRNA but increase IL-1β
mRNA; that at the NB4 cell concentrations used (106 cells/
ml), TNF and to a lesser extent IL-1β partially contribute to
TF expression; and that NF-κB and p38 contribute to TF
expression. Our results that ATRA reduces TF mRNA and
activity in NB4 cells are in agreement with previous results
using this cell line [18, 20–22] and with results obtained with
bone marrow cells from APL patients at different times after
initiation of ATRA treatment [7, 19, 27]. ATRA and ATO both
have similar effects on TF mRNA. However, ATRA reduces
by 90% already within 1 h, whereas the effect of ATO on TF
mRNA is evident only after 6 h.
In HL-60 cells, which lack the 15;17 chromosomal trans-
location, ATRA acted more slowly on TF mRNA and a max-
imal of 35% inhibition was obtained after 3 h, whereas ATO
increased TFmRNAup to twofold. This implies that the effect
of ATRA and ATO on TF expression is different in NB4 and
HL-60 cells.
In NB4 cells, both ATRA and ATO induce the degradation
of the PML-RARα fusion protein [32], which is capable of
stimulating an increased TF expression [18]. Our finding that
Zn2+ stimulation of U937-PR9 cells strongly increases TF and
TNF mRNA (Fig. 2) and that ATO treatment of these Zn2+
stimulated cells reduced TF mRNA is compatible with the
hypothesis that ATRA and ATO reduced TF and TNF via
the degradation of PML-RARα. However, the increase in
IL-1β also induced by Zn2+ stimulation of U937-PR9 cells
(Fig. 2) contrasts with the fact that neither ATRA nor ATO
reduced this cytokine. In addition, the rapidity of the effect of
ATRA on TF expression rather suggests a primary action that
is independent of PML-RARα degradation. Indeed, one hy-
pothesis for APL pathogenesis suggests that PML/RARα re-
cruits co-repressors and histone deacetylases to their putative
target genes at physiological concentrations of ATRA [46,
47]. A primary effect of ATRA at pharmacological concentra-
tions is to change the PML-RARα fusion protein from a re-
pressor into a transcriptional activator [48]. It is therefore like-
ly that the effect of ATRA on TF reduction is not direct but
rather related to upregulation of a protein that negatively reg-
ulates TF expression. The rapid ATRA-induced reduction in
TF mRNA, with a half-life of less than 1 h, is compatible with
the short TF mRNA half-life previously described for TNF-
stimulated endothelial cells [49]. A plausible mechanism for
the effect of ATRA would therefore be an increase in TF
mRNA turnover rather than a mechanism dependent on
PML-RARα degradation; the latter may be relevant after
ATO treatment. The rapid turnover of TF mRNAmay involve
an AU-rich element (ARE) in the TF mRNAmolecule, which
is known to recruit RNA-degrading enzymes [50]. Indeed,
ARE interacting proteins such as tristetraprolin and PARP14
exert selective posttranscriptional control of TF in macro-
phages [51, 52].
We complemented our analysis on TF mRNAwith assays
of procoagulant activity of NB4 cells and of NB4 cell-derived
microparticles. Several lines of evidence point to a role of
microparticles emitted by leukemic cells in the disturbances
of hemostasis [13, 14, 53]. These microparticles may exert a
direct or an indirect procoagulant effect. Indeed, Fang et al.
[54] have shown that vascular endothelial cells may uptake
NB4-derived microparticles and microparticle-derived TF
may make the endothelial cells procoagulant. Coagulation
studies were not only the chromogenic factor Xa generation
assay but also the CAT assay [35, 55]. The latter is thought to
be more relevant to the in vivo phenomena, because it takes
into account all factors that contribute to the pro- and antico-
agulant activities of NB4 cells and microparticles [56]. The
effect of ATRA on TF protein and activity is delayed with
respect to its rapid effect on TF mRNA and is only evident
at 24 h. Even then, significant procoagulant activity is still
detected and this information is quite relevant in the context
of reducing hemorrhagic complication in the early treatment
phase [57]. In agreement with previous reports [58, 59], we
found with the CAT assay that cells and microparticles bring
both TF and an appropriate surface, since a substantial inhibi-
tion was obtained in presence of anti-TF antibody and since
we did not add extra phospholipids. Of note, inhibition of
thrombin generation as assessed with the CATassay appeared
to be less than that measured with the artificial Xa generation
assay. This underscores the importance to assay TF activity
under more physiological conditions.
Exposure of NB4 cells to ATRA resulted in a reduction of
TNF mRNA, as well as an increase in IL-1β mRNA. There
are previous reports on the absence of an effect of ATRA on
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TNF mRNA [24, 25]. It remains to be established whether the
difference in effect of ATRA is due to differences in timing of
TNF mRNA measurements (up to 24 h versus 2 to 4 days) or
in ATRA concentration (0.5 versus 10 μM). On the other
hand, the ATRA-induced increase in IL-1β expression is in
agreement with previous reports [24, 25]. The effect of ATRA
in reducing TNF mRNA appears to be specific for NB4 cells,
because ATRA treatment of HL60 acute myeloid leukemia
cells had no effect on TNF mRNA (this study) or increased
TNF mRNA [24]. TNF is known to increase TF expression in
different cell types. The ATRA-induced reduction of TNF
mRNA occurs later than that of TF mRNA (several hours
versus 30 min). Therefore, the decrease in TNF expression
cannot explain the effect of ATRA on TF mRNA.
However, TNF does contribute, at least partially, to TF
expression in NB4 cells because inhibition of TNF by using
adalimumab consistently reduced in TF mRNA by 25% and
reduced the procoagulant activity ofNB4 cells andNB4 cell-
derived microparticles. The contribution of IL-1β to TF
mRNA was less than that of TNF, and we could not detect
an effect of IL-1β inhibition on CAT activity expressed by
NB4 cells and NB4 cell-derived microparticles. In APL pa-
tients, the contribution of TNF or of IL-1β may be higher
becauseNB4 cell densities used in our experiments aremuch
lower than the densities of leukemic cells encountered in
patient’s blood and bone marrow. We were unable to study
the contribution of TNF or of IL-1β at higher cell concentra-
tions because, in our in vitro cell culture system, these are
limited to approximately 106 NB4 cells/ml due to acidifica-
tion and exhaustion of the cell culture medium within 24 h.
Leukemia cell-derived cytokines may also be relevant for
thrombo-hemorrhagic events in APL patients, because they
increase TF expression by endothelial cells [60–62] and
monocytes [63].
We observed that inhibition of the signaling intermediates
p38 or of NF-κB that act downstream of TNF or IL-1β had a
more pronounced effect (38% and 62% inhibition of TF
mRNA, respectively), than selective inhibition of TNF or
IL-1β alone (28% and 20% inhibition of TF mRNA, respec-
tively), whereas inhibition of jun kinase had no effect.
However, it has to be stressed that inhibition of p38 results
in a strong increase in TNF expression (sixfold) and an even
more pronounced increase in IL-1β expression (26-fold).
Thus, it appears that key elements of the signaling pathways
of inflammatory cytokines are also involved in the regulation
of their production. An unexpected finding of our study was
that inhibition of NF-κB induced cell death within a few
hours. The resulting liberation of TF-bearing microparticles
may explain the increase in procoagulant activity of NB4
cell-derived microparticles, as measured with the CAT assay,
despite an initial reduction in TF mRNA.
The effect of NF-κB inhibition should stimulate more de-
tailed studies on the importance of NF-κB for APL cell
survival, the mechanisms by which NF-κB inhibition induces
cell death and whether NF-κB inhibition can be used as ad-
junct therapy in APL [64, 65]. The consequences of potential
effects of NF-κB inhibition on APL cell survival should be
carefully evaluated, as the apoptotic cells and the cell-derived
microparticles express phosphatidylserine at their surface and
may thereby exacerbate thrombo-hemorrhagic complications,
despite an initial reduction in TF mRNA, but not yet in TF
protein.
In conclusion, ATRA and ATO reduce expression by NB4
APL cells of both TF and TNF and inhibition of TNF or IL-1β
or of the inflammatory signaling intermediates p38 or NF-κB
also reduces TF.
Thus, TNF and IL-1β have a regulatory function on TF
expression by NB4 APL cells, but the effect of ATRA and
ATO on TF can only partially be accounted for their impact on
these cytokines. The results presented here should stimulate
further in vitro and in vivo preclinical studies to determine to
what extent inhibition of inflammatory cytokines or inflam-
matory signaling intermediates can be used for the further
development of adjunct therapies of APL.
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